QUVIVIQ

This brand name is authorized in Austria, Estonia, Spain, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom, United States

Active ingredients

The drug QUVIVIQ contains one active pharmaceutical ingredient (API):

1 Daridorexant UNII 9X9581N56R - DARIDOREXANT HYDROCHLORIDE

Daridorexant is a dual orexin receptor antagonist, acting on both orexin 1 and orexin 2 receptors and equipotent on both. The orexin neuropeptides (orexin A and orexin B) act on orexin receptors to promote wakefulness. Daridorexant antagonises the activation of orexin receptors by the orexin neuropeptides and consequently decreases the wake drive, allowing sleep to occur, without altering the proportion of sleep stages. Read about Daridorexant

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
QUVIVIQ Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N05CM	Other hypnotics and sedatives	N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives
Discover more medicines within N05CM

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1882470, 1882481, 1882492, 1882504
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1221638002, 1221638003
Country: IT	Agenzia del Farmaco	Identifier(s): 050050018, 050050020, 050050032, 050050044, 050050057, 050050069
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1094658, 1094659, 1094660, 1094661, 1094873, 1094874
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100468984, 100468991
Country: US	FDA, National Drug Code	Identifier(s): 80491-7825, 80491-7850